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A B S T R A C T
Nanoparticles (NPs) based on biocompatible and biodegradable polymers such as poly(lactic-co-glycolic acid)
(PLGA) and polycaprolactone (PCL) represent effective systems for systemic drug delivery. Upon injection into
the blood circuit, the NP surface is rapidly modified due to adsorption of proteins that form a ‘protein corona’
(PC). The PC plays an important role in cellular targeting, uptake and NP bio-distribution. Hence, the study of
interactions between NPs and serum proteins appears as key for biomedical applications and safety of NPs. In the
present work, we report on the comparative protein fluorescence quenching extent, thermodynamics of protein
binding and identification of proteins in the soft and hard corona layers of PLGA and PCL NPs. NPs were pre-
pared via a single emulsion-solvent evaporation technique and characterized with respect to size, zeta potential,
surface morphology and hydrophobicity. Protein fluorescence quenching experiments were performed against
human serum albumin. The thermodynamics of serum protein binding onto the NPs was studied using iso-
thermal titration calorimetry. Semi-quantitative analysis of proteins in the PC layers was conducted using gel
electrophoresis and mass spectrometry using human serum. Our results demonstrated the influence of particle
hydrophobicity on the thermodynamics of protein binding. Human serum proteins bind to a greater extent and
with greater affinity to PCL NPs than PLGA NPs. Several proteins were detected in the hard and soft corona of the
NPs, representing their unique proteome fingerprints. Some proteins were unique to the PCL NPs. We anticipate
that our findings will assist with rational design of polymeric NPs for effective drug delivery applications.
1. Introduction
Polymeric biodegradable nanoparticles (NPs) are among the most
explored systems for drug delivery. Indeed, there are a number of FDA
approved nanomedicines which are based on polymeric biodegradable
NPs [1]. Amongst the most widely used polymers in the synthesis of
biodegradable NPs are the polyesters poly(lactic-co-glycolic acid)
(PLGA) and polycaprolactone (PCL) [2–5]. PLGA is composed of the
monomers lactic and glycolic acid which impart a hydrophobic char-
acter to the polymer. Typically, oil in water (O/W) nano-emulsions
prepared from the polymer are useful for achieving encapsulation of
hydrophobic drug cargo and sustained drug release [6]. The more hy-
drophobic polymer PCL is formed by the polymerization of ε-
caprolactone, and nano-emulsions from this polymer also serve the
same purpose as those of PLGA [5].
NPs are able to alter the pharmacokinetics (PK) of drugs [7]; a result
of reversible partitioning of NPs between blood, tissue and cellular
compartments whilst releasing drug cargo within these compartments.
While one can engineer and characterize a NP in vitro, when introduced
to blood, the NP attains a new identity (i.e. a bio-identity) primarily due
to adsorption of proteins (as well as lipids) which coat the NP’s surface
forming what is known as a ‘protein corona’ (PC) [8]. Lipids are
transported in blood by lipoproteins, and the corona around NPs has
been reported to be enriched by lipoproteins [9]. It is the bio-identity of
the NP that ultimately dictates the NP’s PK, as well as its targeting,
uptake and bio-distribution profile within the body [10–12]. The PC is a
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fingerprint, unique for each NP type and influenced largely by NP size,
shape and surface chemistry [11–13]. Adsorbed layers of proteins, with
one layer strongly bound to the NP’s surface and other layer(s), weakly
bound and in dynamic exchange with the environment have been de-
scribed [8,9,14,15]. Therefore, knowledge of the composition and
spatial organization of the PC covering the NP carrier is essential. This
consideration provides the context for determining structure-activity
relationships of nanomedicines and also supports a rational approach to
NP design. In other words, characterization of the PC formed on NPs
could assist to ‘back engineer’ NPs, which will attain a desired PC in vivo
and resultant PK and pharmacodynamic profile, i.e. a quality by design
approach. Such an approach could accelerate the development and
translation of nanomedicines [16,17].
In recent times, there have been studies to characterize the PC
formed on NPs [12,14,18–22]. However, much focus has been placed
on polystyrene and metallic NPs (e.g. gold and silver NPs [22–24]).
While other studies have reported the PC on PLGA NPs [20,21], the
present study sought to compare the PC composition between poly
(vinyl alcohol) (PVA) stabilized PLGA and PCL NPs in human serum,
and to determine the thermodynamics of protein binding. We have
applied techniques such as gel electrophoresis coupled with liquid
chromatography mass spectrometry analysis (LC–MS/MS), fluorescence
quenching and isothermal titration calorimetry (ITC) to characterize
the PC and determine protein binding thermodynamics, respectively.
We worked with ‘native’ PLGA and PCL NPs, i.e. in the absence of any
surface modifications, in order to characterize the intrinsic behaviour of
these NPs in the biological fluids. The average size and size distribution
of the PLGA and PCL NPs synthesized in this study is similar to that
reported in many studies in literature, making the findings of this study
generally applicable.
2. Materials and methods
2.1. Materials
The following products were purchased from Sigma Aldrich: PVA,
(Mw 13.000–23.000), PLGA (ratio of lactic acid:glycolic acid 50:50; Mw
30 000–60 000), PCL (average Mw 14 000, average Mn 10.000 by gel
permeation chromatography), human serum albumin ((HSA), ≥ 99 %
lyophilized powder, fatty acid and globulin free), human serum (from
human male AB plasma, USA origin, sterile-filtered), rose Bengal (RB),
lithium dodecyl sulphate (LDS), dithiothreitol (DTT), sucrose (≥ 99.5
%), sodium hydroxide (NaOH), monopotassium phosphate (KH2PO4),
dipotassium phosphate (K2HPO4), ammonium bicarbonate (NH4HCO3),
formic acid (FA), trifluoroacetic acid (TFA), acetonitrile (ACN), tris-
carboxyethyl phosphine (TCEP) and iodoacetamide (IAA).
Dichloromethane (DCM) and hydrochloric acid (HCl) were supplied by
Kimix Chemicals, South Africa. Sequencing grade modified trypsin was
purchased from Promega (USA). Milli-Q water was obtained from
Thermo Scientific Barnstead™ Smart2Pure™ Water Purification System.
2.2. Synthesis of NPs
The method of NPs synthesis was adapted from our prior work [25].
Briefly, 0.5 % (w/v) of PVA was dissolved in Milli-Q water at 120 °C
within 1 h under vigorous magnetic stirring. The solution was cooled
down and filtered through 0.22 μm filter. Simultaneously, 1 % (w/v) of
PLGA or PCL polymer was dissolved in DCM at room temperature.
Thereafter, 10 volumes of PVA aqueous solution were mixed with 1 vol
of PLGA or PCL solution under probe sonication (Bandelin SONOPULS,
HD2070, 55 % amplitude) for 3min in an ice bath. The PLGA or PCL
solution was added dropwise within the first minute of sonication.
Evaporation of DCM was performed using a rotavapor (Büchi Rotavapor
R2, Germany) for 15min. PLGA or PCL NPs were collected after a single
wash with Milli-Q water and 15min of centrifugation at 10 000 x g.
Finally, NPs were re-dispersed in Milli-Q water and sucrose (as
cryoprotectant) was added to the NPs suspension prior freeze-drying
(10:1 w/w). After freeze-drying NPs were stored in a desiccator prior to
characterization.
2.3. Characterization of NPs size, zeta potential and shape
Particle size (z-average hydrodynamic diameter, Hd) and zeta po-
tential of NPs were determined using a Zetasizer Nano ZS90 (Malvern
Instruments Ltd.). NPs size and polydispersity index (PDI) were de-
termined using dynamic light scattering after freeze-drying following
by re-dispersion of NPs in Milli-Q water for 5min in ultrasonic bath.
The average values were obtained from 3 different samples; 3 mea-
surements with 10 scans per measurement were performed for each
sample at 25 °C. The errors were calculated as standard deviations (s.d.)
of each average value. For zeta potential measurements, freeze-dried
NPs were also re-dispersed in Milli-Q water for 5min in ultrasonic bath.
Zeta potential values were determined using laser Doppler microelec-
trophoresis averaging 3 measurements with 10 scans per measurement
for 3 different samples. Scanning electron microscopy (SEM) was per-
formed on Zeiss AURIGA® SEM working at 5 kV voltage and using NPs
freeze-dried without cryoprotectant (sucrose). A small quantity of NPs
was spread on carbon double-side tape stuck on SEM stub. Samples
were sputter-coated with gold-palladium prior to any observation.
2.4. Characterization of surface hydrophobicity of the NPs
The hydrophobicity of the PLGA and PCL NPs was measured using
the surface adsorption method described by Xiao and Wiesner [26]. The
relative adsorption of Rose Bengal (RB) onto the NPs was evaluated.
12.5 μg/ml of RB was added to PLGA and PCL NPs separately (NP
concentrations ranged from 0.1–2mg/ml in PBS pH 7.4). Controls of RB
in PBS to account for any adsorption of RB to tubes were prepared.
Samples were incubated for 3 h at room temperature. Thereafter, NPs
were settled by centrifugation at 15 000 x g at 4 °C for 20min. The
absorbance of free RB in the supernatant was determined by UV–vis
absorption spectroscopy at 542 nm. A linear relationship between ab-
sorbance and RB concentration in PBS was pre-established over the
range 6.25–50 μg/ml (r2= 0.9991). The percentage of adsorption of RB
onto the NPs was calculated using the following equation (Eq. (1)):
=
×
% adsorption of RB Concentration of RB in control - Concentration of RB in sample supernatant
Concentration of RB in control
100 (1)
2.5. Determination of extent of protein fluorescence quenching
Steady-state fluorescence quenching measurements were performed
against HSA (1.32 μM) in the presence of an increasing concentration of
either PLGA or PCL NPs (0.1–2mg/ml). The HSA-NPs suspensions (in
PBS pH 7.5) were incubated in a 96 well plate (low protein binding) for
1 h at 37 °C with gentle shaking. Samples were analyzed in a fluores-
cence microplate reader (Synergy Mx, BioTek Instruments, USA) and
fluorescence spectra were obtained after 5min in the range of
320−400 nm after excitation at 280 nm. HSA contains one tryptophan
residue, which makes it adsorb and fluoresce light at these wavelengths.
HSA, PLGA and PCL NPs alone in PBS were also included as controls.
The HSA is expected to bind to the NPs resulting in a quenching of
fluorescence. The area under each fluorescence curve (AUC) was in-
tegrated and used to calculate the percentage of protein fluorescence
quenching using the following equation (Eq. (2)):
= +
×
% Quenching (Fluorescence (AUC) of HSA fluorescence (AUC) of HSA NPs)
Fluorescence (AUC) of HSA
100 (2)
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2.6. Determination of thermodynamics of protein binding to the NPs using
isothermal titration calorimetry
ITC experiments were carried out on Nano ITC calorimeter (TA
Instruments, USA) at 37 °C. A dispersion of PLGA or PCL NPs in PBS pH
7.4 (2.2mg/ml) was poured into the sample cell and HSA (40mg/ml in
PBS pH 7.4) or human serum solution (1:1 vol dilution in PBS pH 7.4)
was progressively titrated (25×10 μl). The time between the titration
steps was fixed to 700 s such that the system reached an equilibrium
state. The NP dispersion in the sample cell was constantly stirred at
250 rpm during the experiment. In order to determine the heat of di-
lution, pure PBS was titrated to PBS containing either NP dispersion (i.e.
NPs and sucrose), or sucrose. For these blank experiments, the con-
centrations were the same as those mentioned above. Analysis of ITC
curves was performed using the NanoAnalyze™ software (TA
Instruments, USA) using an independent model. The thermodynamic
parameters that characterize the protein binding were obtained using
the following equations (Eqs. (3) and (4)):
=G H T S (3)
=G RT lnKB (4)
where ΔG is the change in Gibbs free energy of binding, ΔH and ΔS are
the enthalpy and entropy changes, respectively, and KB represents the
binding constant. The gas constant R =8.314 J/K.mol.
2.7. Collection and characterization of the NP’s protein corona
The method employed to collect the corona was adapted from
Walkey et al. [23]. A PLGA or PCL NPs suspension (0.4 μg/ml) prepared
in PBS pH 7.5 was added to a human serum (HS) solution at a 1:1 vol
ratio (1ml total). The stock HS was diluted 1:50 in 2X PBS buffer at pH
7.5. The preparations were mixed in low-protein binding centrifuge
tubes (Eppendorf LoBind™ tubes). The negative control consisted of the
same preparation without NPs and the positive control consisted only of
diluted serum. The preparations were incubated for 90min at 37 °C in a
shaking water bath and thereafter the samples were centrifuged at 15
000 x g at 4 °C for 15min. The supernatant containing unbound pro-
teins was collected as ‘wash 1’. 1 ml of 10mM PBS buffer at pH 7.5
supplemented with 0.05 % (w/v) Tween 20 was added to the pellet. The
pellet was reconstituted by bath sonication for 5min and thereafter
centrifuged at 15 000 x g at 4 °C for 15min. The supernatant containing
the weakly bound corona was collected as ‘wash 2’. PBS buffer (988 μl)
at pH 7.5, 8 μl of 4X lithium dodecyl sulphate and 4 μl of 500 nM DL-
dithiothreitol (DTT) were added to the pellet. The latter was recon-
stituted by vortexing, and thereafter incubated at 70 °C for 1 h in a
shaking water bath. The samples were then centrifuged at 15 000 x g at
4 °C for 15min, and the supernatant containing the strongly bound
corona was collected as ‘wash 3’. All protein and corona samples col-
lected were stored at -80 °C until analysis. Fig. S1 in Supplementary
data is a schematic of the corona collection protocol.
2.8. Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) analysis of the corona
A fraction of each wash (3 μg of each protein sample) was denatured
and size fractionated on a 12 % SDS-PAGE gel for 90min at 120 V. After
gel electrophoresis, the SDS-PAGE gel was stained with Coomassie
Brilliant Blue G-250 for 30min and transferred to a de-staining solution
(10 % glacial acetic acid and 1 % glycerol) for 2 h. The resolved protein
bands were visualized using the ENDURO™ GDS Gel Documentation
System (Labnet International, Edison, NJ). Gel processing and in-gel
digestion were performed as described by Piersma et al. [27] with slight
modifications. The SDS-PAGE gel was divided into different zones prior
to in-gel tryptic digestion. Gel bands were excised from the Coomassie-
stained SDS-PAGE gel and transferred to 2ml LoBind™ Eppendorf tubes
(Hamburg, Germany) for further processing. Gel bands were washed/
de-stained in 200 μl of 25mM NH4HCO3/50 % ACN for 45min. The gel
bands were dehydrated in 100 μl of ACN and reduced in 2mM TCEP in
25mM NH4HCO3 for 15min at room temperature with moderate agi-
tation. Excess TCEP was removed and cysteine residues carbamido-
methylated with 20mM iodoacetamide in 25mM NH4HCO3 for 30min
in the dark at room temperature. The gel bands were washed with
25mM NH4HCO3 followed by another dehydration step. Proteins were
digested by rehydrating the gel cubes in a trypsin solution (10−20 ng/
μl) in 25mM NH4HCO3 and incubating at 37 °C overnight. Peptides
were extracted from gel cubes with 30 % ACN/0.1 % TFA for 45min at
room temperature with intermittent vortexing. The samples were dried
down to remove residual NH4HCO3, re-dissolved in 0.1 % TFA and
further purified and concentrated using C18 ZipTip® according to
manufacturer’s instructions. The purified peptides were dried in a
SpeedVac® followed by resuspension in 10 μl of 0.1 % TFA. Samples
were stored at −20 °C prior to nano-flow reversed-phase LCeMS/MS
analysis.
2.9. Peptide fractionation and detection using LC–MS/MS
A high-pressure liquid chromatography system running at nano-
flow rates was used for peptide fractionation prior to mass spectrometry
analysis. The method for LC–MS/MS analysis was adapted from [28].
Chromatography was performed using a Thermo Scientific Ultimate
3000 RSLC equipped with a 2 cm x100 μm C18 trap column and a 35 cm
x75 μm C18 analytical column (Luna C18, 5 μm; Phenomenex). The
solvent system employed was loading: 2 % ACN : water; 0.1 % FA;
Solvent A: 2 % ACN : water; 0.1 % FA and Solvent B: 100 % ACN :
water. Samples were loaded onto the trap column using loading solvent
at a flow rate of 15 μl/min from a temperature controlled autosampler
set at 7 °C. The flow rate was set to 500 nl/min and a gradient generated
as follows: 2–10 % solvent B over 5min; 5 %–25 % solvent B from 5 to
50min using Chromeleon non-linear gradient 6, 25 %–45 % from 50 to
65min. Chromatography was performed at 50 °C and the outflow de-
livered to the mass spectrometer through a stainless steel nano-bore
emitter. Detection was performed using a Thermo Scientific Fusion
mass spectrometer equipped with a Nanospray Flex ionization source.
The sample was introduced through a stainless-steel emitter. Data were
collected in a positive mode with spray voltage set to 2 kV and ion
transfer capillary set to 275 °C. Spectra were internally calibrated using
polysiloxane ions at m/z=445.12003 and 371.10024. MS1 scans were
performed using the orbitrap detector set at 120 000 resolution over the
scan range 350–1650 with AGC target at 3 E5 and maximum injection
time of 40ms. Data were acquired in profile mode. MS2 acquisitions
were performed using monoisotopic precursor selection for ion with
charges +2-+6 with error tolerance set to +/- 0.02 ppm. Precursor
ions were excluded from fragmentation once for a period of 30 s. Pre-
cursor ions were selected for fragmentation in higher energy dissocia-
tion (HCD) mode using the quadrupole mass analyzer with HCD energy
set to 32.5 %. Fragment ions were detected in the orbitrap mass ana-
lyzer set to 15 000 resolution. The AGC target was set to 1E4 and the
maximum injection time to 45ms. The data were acquired in centroid
mode.
2.10. Protein validation and data analysis
The raw files generated by the MS were imported into Proteome
Discoverer v1.4 software (Thermo Scientific, USA) and processed using
Sequest algorithm. Database interrogation was performed against a
concatenated database created using the Uniprot human database with
semi-tryptic cleavage allowing for 2 missed cleavages. Precursor mass
tolerance was set to 10 ppm and fragment mass tolerance set to 0.02 Da.
Deamidation (NQ) and oxidation (M) was allowed as dynamic mod-
ifications and carbamidomethylation of C as static modification.
Peptide validation was performed using the peptide validator node set
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to search against a decoy database with strict false discovery rate (FDR)
of 1 % and delta Cn of 0.1 (delta Cn being the measure of specificity of
fit of the experimental data against that in the database). The result files
were imported into Scaffold 4.8.8 and identified peptides validated
using the X!Tandem search algorithm included in Scaffold. Peptide and
protein validation were done using the Peptide and Protein
Prophet algorithms. Protein quantitation was performed using Fischer’s
Exact Test on the paired data with the Benjamini-Hochberg correction
applied. Protein identifications were accepted if they could be estab-
lished at greater than 95 % probability and contained at least two un-
ique identified peptides.
2.11. Statistical analysis
All the data are presented as mean ± s.d. (n ≥ 3), unless otherwise
noted. The statistical analysis of the data was carried out using the
Student’s t-test or two-way ANOVA using GraphPad Prism 8.10 soft-
ware (GraphPad, CA). Statistical differences were considered at
p<0.05.
3. Results and discussion
3.1. NPs synthesis and characterization
A number of techniques exist to prepare PLGA and PCL NPs such as
emulsification, nanoprecipitation or spray-drying. The most commonly
applied method is based on single emulsion-solvent evaporation [29],
and this method was used to synthesize the NPs in this study.
Both polymers produced particle populations with a polydispersity
index (PDI) of approximately 0.2 (see Fig. 1A). PCL-based NPs had a
larger Hd than PLGA NPs (559 ± 53 nm vs. 416 ± 41 nm, p=0.021)
even though synthesis conditions were the same. This could be due to
the difference in hydrophobicity between the two polymers. In O/W
emulsions, the phenomenon of Ostwald ripening often occurs, i.e. mo-
lecules from small oil droplets can diffuse through the aqueous phase to
join larger oil droplets in order to reach a more thermodynamically
stable state [30]. As PCL polymer is more hydrophobic than PLGA
polymer [31], the oil droplets with dissolved PCL and consequently the
diameter of precipitated PCL NPs will be slightly larger than that of
PLGA NPs, even though the emulsion stabilizer (PVA) is present during
the emulsification. It should be noted that although there was a
significant difference in the z-average Hd between the particle types,
significant overlap in the particle populations (particle size distribu-
tion) was observed, and hence it is not expected that particle size will
play a significant role in influencing protein binding between the two
NP types. Under microscopy, both PLGA and PCL NPs were observed to
be spherical in shape and their surface appeared smooth (Fig. 1B).
The zeta potential was determined on freeze-dried NPs re-dispersed
in water. The zeta potential of both types of NPs were negative and of
approximately the same value, i.e. -18 ± 2mV and -18 ± 3mV re-
spectively for PLGA and PCL NPs (Fig. 1A). Therefore, aggregation of
nanoparticles could not be observed due to sufficient electrostatic re-
pulsions, indicating a good NPs stability in suspension.
3.2. Hydrophobicity of NPs surface
The hydrophobicity of the PLGA and PCL NPs was characterized
using a dye absorption assay. The PCL NPs were observed to be more
hydrophobic than the PLGA NPs (Fig. 2). The differences in RB ad-
sorption were more apparent at the higher NPs concentration. No sig-
nificant difference was found at low NPs concentrations (0.1mg/ml and
0.5 mg/ml) with p-values of 0.1527 and 0.8472, respectively. However,
a significant difference was observed at NPs concentration of 2mg/ml
(p= 0.0037), and % adsorption of RB was 40.5 ± 2.7 % and
27.7 ± 5.6 % onto the PCL and PLGA NPs, respectively. RB is nega-
tively charged and some repulsion by the negative surface of the PLGA
and PCL NPs would be expected, although this effect is expected to play
a relatively minor role (in RB binding) in relation to the hydrophobicity
of the NP surface [26]. However, the relative hydrophobicity of the NPs
provides an indication of the expected extent and rate of protein
binding, with the more hydrophobic PCL NP anticipated to bind more
proteins at a faster rate in comparison to the less hydrophobic NPs [32].
3.3. Fluorescence quenching
The PCL and PLGA NPs (0.1–2mg/ml) were incubated for 5min
with HSA and the change in fluorescence maxima of HSA was assessed.
A significant blue shift of the HSA emission maxima from 335 to
330 nm and 325 nm was observed consequent to the addition of PLGA
and PCL NPs, respectively (Fig. 3). This indicates a shift of the HSA
fluorophore (Tryptophan 214) to a more nonpolar environment and is a
result of the hydrophobic interactions with the NPs [15,33]. The more
Fig. 1. (A) z-average hydrodynamic diameter (Hd), PDI, and zeta potential of PLGA and PCL NPs; (B) SEM images of PLGA and PCL NPs, SEM images were collected
from freeze-dried NPs in the absence of sucrose cryoprotectant.
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blue-shifted HSA/PCL NPs emission maxima also confirms the more
hydrophobic nature of the PCL NPs compared to the PLGA NPs.
A higher percentage of HSA fluorescence quenching in presence of
PCL NPs when compared to PLGA NPs was observed (see column
graphs in Fig. 3). However, the statistical analysis shows no significant
differences between the percentage quenching with both NPs at con-
centrations of 0.1, 0.5 and 2mg/ml.
3.4. Thermodynamics of protein binding to PLGA and PCL NPs
ITC is a powerful analytical tool that directly measures the heat
released or absorbed during a biomolecular binding event and helps to
measure the binding affinity of two biomolecules. When substances
bind, heat is either generated or absorbed. Measurement of heat allows
accurate determination of binding constants (KB) and enthalpy. The ITC
raw heat profiles obtained during these analyses showed that the
binding interaction between the PLGA NPs and HSA or serum, as well as
between the PCL NPs and HSA or serum was exothermic (data not
shown). Using an independent model and Eqs. (3) and (4), we obtained
the thermodynamic values resumed in Table 1.
3.4.1. Kinetics of binding of HSA and serum to PLGA NPs
Binding constant values of polymeric NPs-protein interactions gen-
erally vary between 105 and 107 [34–37]. The KB value obtained here
(2.43 ͯ 105) is within the lower limit of this range indicating a relatively
low binding affinity of HSA to the PLGA NPs. Biomolecular interactions
usually involve solvent reorganization (desolvation and solvation) and
non-covalent bond formation. When ΔH is negative, this is an indication
of the exothermic process of non-covalent bond formation which is
therefore the case with the interaction of HSA with PLGA NPs. If ΔS is
positive, this is indicative of desolvation occurring during the com-
plexation process. The fact that both ΔH and -TΔS are negative suggests
that the binding of the protein to the NPs is governed by non-covalent
bonding [38].
For the complexation of human serum with the PLGA NPs, we ob-
served a very small KB value (3.01 ͯ 103) which indicates that serum has
even lower binding affinity to PLGA NPs than HSA. Considering the
other thermodynamic parameters, it becomes apparent that the binding
of serum proteins with these NPs is also governed by non-covalent
bonding. Preliminary results obtained from MicroScale Thermophoresis
(Instrument and settings: Monolith® NT.115Pico, NanoTemper
Technologies GmbH) gave a dissociation constant of 5.48 μM indicating
a weak interaction between HSA and PLGA NPs, which is further ver-
ifying the data obtained in these ITC experiments
3.4.2. Kinetics of binding of HSA and serum to PCL NPs
In comparison with PLGA NPs, HSA shows a lower binding affinity
to the PCL NPs (KB=2.43 ͯ 104, Table 1). The negative ΔH value implies
Fig. 2. Percentage (%) adsorption of Rose Bengal (RB) to PCL and PLGA NPs.
Higher % adsorption onto PCL is observed. A statistically significant difference
in adsorption is observed at NPs concentration of 2 mg/ml (p value=0.0037).
Fig. 3. Fluorescence intensity spectra of HSA alone and in the presence of different concentrations of PLGA (A) and PCL (B) NPs after 5min of incubation at 37 °C.
The fluorescence data were used to calculate the percentage of HSA fluorescence quenching in presence of varying concentrations of PLGA and PCL NPs. Results
shown are the mean ± s.d.
Table 1
Thermodynamic parameters for the association of HSA and serum to PLGA and
PCL NPs.
ΔH (kJ/mol) KB -TΔS (kJ/mol) ΔS (J/mol)
PLGA NPs + HSA −9.11 2.43 ͯ 105 22.87 73.74
PLGA NPs+ serum −4.17 3.01 ͯ 103 16.48 53.13
PCL NPs + HSA −15.96 2.43 ͯ 104 10.09 32.52
PCL NPs+ serum −11.58 7.52 ͯ 105 23.31 75.16
M. Ndumiso, et al. Colloids and Surfaces B: Biointerfaces 188 (2020) 110816
5
that non-covalent bonding occurred between the NPs and the protein
with desolvation forming part of the complexation process. On the
other hand, proteins from human serum present a higher binding affi-
nity to PCL NPs (as compared to HSA protein) which can also be clas-
sified as non-covalent bonding. Moreover, serum proteins have much
higher binding affinity with PCL NPs (KB=7.52 ͯ 105) than with PLGA
NPs (3.01 ͯ 103). This is probably due to higher hydrophobicity of PCL
NPs vs. PLGA NPs as demonstrated by the fluorescence quenching as-
says.
3.5. Detection of NPs protein coronas with SDS-PAGE
One dimensional polyacrylamide gel electrophoresis was performed
to qualitatively and semi quantitatively analyze the corona fingerprint,
i.e. unbound (wash 1), weakly bound corona (wash 2) and strongly
bound corona (wash 3) to PLGA and PCL NPs, respectively. A small
fraction of each wash was size fractionated and visualized on a 12 %
SDS gel (see Fig. S2 in Supplementary data). Well resolved protein
bands with similar profiling patterns were observed for each wash with
the exception of wash 3. Only one distinct band was detected in wash 3
of PCL NPs whereas three bands were detected in the same wash for
PLGA NPs. Protein bands were excised from the gel, trypsin digested
and the resulting peptides analyzed using LCeMS/MS.
3.6. Identification of proteins in the corona layers of PCL and PLGA NPs
The protocol used in this study was able to identify 29 and 10
proteins in all fractions of the PCL and PLGA NPs, respectively
(Table 2). Only proteins that contained at least two unique peptides
with a probability score equal to or greater than 95 % were accepted as
positive identities [39].
Distinct differences in protein identifications were observed
between PLGA NPs and PCL NPs fractions. For example, apolipopro-
teins (APOA, APOB, APOE) were only identified in the weakly and
strongly adsorbed fractions of PCL NPs. Apolipoproteins also contain
lipid binding domains which are preferentially adsorbed by hydro-
phobic materials [10,40,41]. Interestingly, the binding of apolipopro-
tein E, only present in the weakly bound corona of PCL NPs, is one of
the main types of proteins which adsorb on liposomes and polymeric
NPs [42] and not inorganic NPs [43]. Kreuter and co-workers suggested
that apolipoprotein E plays a paramount role in the delivery of a
number of NP-bound drugs across the blood-brain barrier (BBB) [44],
brought about by the initiation of a receptor-mediated endocytosis
across the BBB, which could influence the intracellular transport of
nanocarriers in vivo [45].
Other proteins that were identified in the weakly and/or strongly
adsorbed fractions of PCL NPs included immunoglobulins (IGG1, IGK,
IGHA, HV374, KV320 and IGLC), vitronectin (VTNC), transferrin
(TRFE), complement proteins (C3 and C5), haptoglobin, antithrombin-
III, alpha-I-antitrypsin, alpha-1B-glycoprotein, ceruloplasmin, heparin
cofactor 2, hemopexin, cystatin-A, inter-alpha-trypsin inhibitor heavy
chain H1, alpha-1-antichymotrypsin, plasma protease C1 inhibitor and
Insulin-like growth factor-binding protein complex acid labile. Similar
findings were reported for hydrophobic NPs and for PEG-modified PCL
NPs [46,47]. The presence of transferrin on the weakly adsorbed layer
may assist with targeting of the PCL NPs, particularly for cancer therapy
[48].
3.7. Semi-quantitative analysis of the PCL NPs and PLGA NPs corona
proteins
In an attempt to differentiate the protein/surface affinity between
the two NP types, we comparatively analysed the data of each wash
fraction. The relative quantification was elaborated statistically using
Table 2
List of positively identified proteins in the unbound (wash 1), weakly bound (wash 2) and strongly bound corona (wash 3) of the PCL and PLGA NPs following
incubation of the NPs with human serum for 90min. The percentages represent the probability scores of the proteins.
Identified proteins Accession numbers Molecular Weight (kDa) PCL NPs PLGA NPs
wash 1 wash 2 wash 3 wash 1 wash 2 wash 3
Serum albumin ALBU 69 100 % 100 % 100 % 100 % 100 % 100 %
Apolipoprotein A-I P02647|APOA1 30 100 % 100 % 100 % 100 % – –
Apolipoprotein B-100 APOB 516 100 % 100 % – – – –
Serotransferrin TRFE 77 100 % 100 % 100 % 100 % – –
Complement C3 CO3 187 100 % 100 % 100 % 100 % – –
Immunoglobulin gamma-1 heavy chain P0DOX5|IGG1 49 100 % 100 % 100 % 100 % – –
Alpha-2-macroglobulin A2MG 163 100 % 100 % – 98% 100 % –
Haptoglobin HPT 45 100 % 100 % – 54%a 92 %a –
Antithrombin-III ANT3 53 100 % 100 % – – – –
Immunoglobulin kappa light chain P0DOX7|IGK 23 100 % 100 % 64 %a – – –
Complement C4-B CO4B 193 – 100 % – 72 %a 100 % –
Inter-alpha-trypsin inhibitor heavy chain H2 P19823|ITIH2 106 100 % 100 % – 96% 100 % –
Alpha-1-antitrypsin A1AT 47 100 % 100 % – – – –
Immunoglobulin heavy constant alpha 1 P01876|IGHA1 106 – 100 % 60 %a 100 % – –
Alpha-1B-glycoprotein A1BG 54 100 % 100 % – 100 % – –
Complement C5 CO5 188 100 % 100 % 40 %a – – –
Ceruloplasmin CERU 122 100 % 100 % – – – –
Heparin cofactor 2 HEP2 57 100 % 100 % – – – –
Hemopexin HEMO 52 100 % 100 % – – – –
Immunoglobulin heavy variable 3-74 HV374 13 – 100 % – – – –
Cystatin-A CYTA 11 100 % 100 % – – – –
Vitronectin VTNC 54 98% 100 % 100 % 93 %a – –
Inter-alpha-trypsin inhibitor heavy chain H1 P19827|ITIH1 101 – 100 % – – – –
Apolipoprotein E APOE 36 – 100 % – – – –
Alpha-1-antichymotrypsin AACT 48 94%a 100 % 100 % – – –
Immunoglobulin kappa variable 3-20 P01619|KV320 12 – 100 % – – 57 %a –
Immunoglobulin lambda constant 2 P0DOY2|IGLC2 11 99% 100 % – – – –
Plasma protease C1 inhibitor P05155|IC1 55 – 100 % – – – –
Insulin-like growth factor-binding protein complex acid labile P35858|ALS 66 – 100 % – – – –
- No proteins detected.
a Proteins with a probability score less than 95 % were not regarded as positive identifications.
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the Fisher’s Exact Test considering the variability across the technical
replicates. The results are reported as volcano plots (Fig. 4), with the
binary logarithm of the fold change (i.e. the amount of a protein in the
corona of a type of NPs versus the amount of the same protein in the
corona of another NPs type) in the x-axis and the –log10 of the adjusted
p-value on the y-axis, accounting for statistical significance. In a one-to-
one comparison between PCL NPs wash 1 (unbound proteins) and PLGA
NPs wash 1, most proteins identified (apart from one) appeared below
the significance threshold due to low internal variability in the wash
fractions of these NPs (Fig. 4A). The protein that appeared above the
significant threshold was inter-alpha-trypsin inhibitor heavy chain H2
(ITIH2) and based on the log2 fold change value, this protein is placed
between -3 and 2. ITIH2 was identified as a protein with the highest
significant correspondence between PCL NPs wash 1 and PLGA NPs
wash 1.
A similar trend was observed for PCL NPs wash 2 (weakly bound
corona) versus PLGA NPs wash 2 where most of the identified proteins
appeared below the significance threshold line (Fig. 4B). Proteins
(ITIH2, CO3, A2MG and A1BG) above the threshold line have log2 fold
change values that range between +1 and +7, which suggests that
they were more likely expressed in the weakly bound corona fraction of
PCL NPs compared to PLGA NPs. Furthermore, this suggests that these
proteins could have a preferential affinity for this specific type of
polymeric NPs, i.e. PCL NPs. In the comparison of PCL NPs wash 3
Fig. 4. Semi-quantitative analysis of weakly bound corona proteins. Volcano plots representing group comparative analysis between (A) PCL NPs wash 1 (unbound
proteins) and PLGA NPs wash 1; (B) PCL NPs wash 2 (weakly bound corona) and PLGA NPs wash 2.
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(strongly bound corona) to PLGA NPs wash 3, all the positively iden-
tified proteins were detected below the significance threshold in-
dicating that the relative amounts of these single proteins did not differ
in the wash fraction of PCL NPs and PLGA NPs (plot not shown).
3.8. Common and unique proteins adsorbed onto the PCL NPs and PLGA
NPs
The Venn diagrams in Figs. 5 and 6 illustrate the number of shared
and unique proteins adsorbed onto PCL NPs and PLGA NPs. Apart from
PCL wash 2 containing eight unique proteins, no unique proteins were
observed in the other two wash fractions of PCL NPs (Fig. 5). However,
a total of 13 proteins were shared between PCL wash 1 (unbound
proteins) and PCL wash 2 (weakly bound corona) whereas one protein
was shared between wash 2 and wash 3 (strongly bound corona). A
total of seven proteins were common amongst the three wash fractions.
For the 10 proteins identified in the wash fractions of PLGA NPs
(Fig. 5), six proteins were unique to PLGA wash 1 and one to PLGA
wash 2. However, no unique proteins were identified in PLGA wash 3
(hard corona) when compared to the other two wash fractions. Fur-
thermore, we observed that two proteins were shared between PLGA
wash 1 and PLGA wash 2, with one protein shared between all wash
fractions of PLGA NPs.
For the comparison between the proteins identified in the unbound
fraction of PCL and PLGA NPs (Fig. 6 PCL_W1 and PLGA_W1), 12
proteins were unique to PCL NPs and only one to PLGA NPs. A total of
eight proteins were shared between these two NPs in the unbound
fractions. Of the 29 proteins identified in the weakly bound fractions,
four were shared between PCL and PLGA NPs and 25 were unique to
PCL NPs (Fig. 6 PCL_W2 and PLGA_W2). No unique proteins were
identified for PLGA NPs in the weakly bound corona. A similar trend
was observed in the strongly bound fraction of PCL and PLGA NPs
(Fig. 6 PCL_W3 and PLGA_W3). Only one protein was shared between
the NPs with seven proteins unique to PCL NPs.
4. Conclusion
We have reported on the interactions of PLGA and PCL NPs with
serum proteins, describing thermodynamics of protein binding and
semi quantitative detection of proteins in the weakly bound and
strongly bound corona layers of (non-surface modified) PLGA and PCL
NPs. Our results indicate that serum proteins have greater affinity
(binding constants) for PCL NPs than PLGA NPs. These observations are
likely attributed to the more hydrophobic nature of PCL NPs in com-
parison to PLGA NPs. Using LC–MS/MS, we detected 29 different pro-
teins present in the corona of PCL NPs and 10 proteins present in the
corona of PLGA NPs, representing their unique proteome fingerprints.
Some proteins were unique to the PCL NPs. Our data was generated
using human serum, and together with other studies conducted using
human plasma, will contribute towards understanding the bio-identity
of NPs and the nature of binding, which is important for rational design
of NP drug delivery systems as this ‘new identity’ influences NPs cell
targeting and uptake as well as the absorption, distribution, metabo-
lism, elimination and toxicity profile of the NPs.
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